Alimentary Health Ltd. receives orphan-drug designation for the treatment of pediatric ulcerative colitis
This new orphan-drug designation builds on the previously granted designation to Alimentary Health for pediatric Crohn's Disease (CD). UC and CD account for the disorders that represent the inflammatory bowel diseases (IBDs).
The pediatric population is defined as patients who are age sixteen or less.
Ulcerative colitis is a disease characterised by remitting and relapsing inflammation of the large intestine. For the treatment of UC, doctors typically prescribe medicines to reduce inflammation or as immunosuppressives.
The disease usually requires these treatments to induce remission but surgery is also occasionally necessary. Paediatric onset leads to a lifelong debilitating disease with significant quality of life implications for UC patients and their families.
Barry Kiely, CEO of Alimentary Health, commented, "the achievement of orphan-drug designation for one of our probiotic technologies is an important step towards having probiotics serve as drug treatment for certain gastrointestinal and inflammatory conditions. This is and will continue to be a key goal of our research efforts."
Alimentary Health is a leader in pioneering the development of safe and effective therapeutics for Gastrointestinal (GI) and other indications.